649 related articles for article (PubMed ID: 22648560)
1. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
2. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
4. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
6. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
7. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
8. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
9. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
10. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4.
Ohbuchi M; Noguchi K; Kawamura A; Usui T
Xenobiotica; 2012 Jul; 42(7):633-40. PubMed ID: 22313038
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
13. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Kodaira C; Uchida S; Yamade M; Nishino M; Ikuma M; Namiki N; Sugimoto M; Watanabe H; Hishida A; Furuta T
J Clin Pharmacol; 2012 Mar; 52(3):432-9. PubMed ID: 21415279
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
17. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Miura M
Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]